The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients

Summary

This is a Phase II, randomized, open-label, multi-center, active-controlled study to assess the safety, tolerability, and efficacy of UB-421 administered as an add-on to the standard ART in ART-treated HIV-1 subjects with stably suppressed HIV-1 plasma VL. The study will be conducted at multiple study centers, designated AIDS hospitals in China.

Timeline

Start

2023-12-01

Primary completion

2024-06-30

Completion

2025-06-30

Drugs

Indications